# A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

> **NCT00983307** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 17 (actual)

## Conditions studied

- Carcinoma, Non-small-cell Lung

## Interventions

- **DRUG:** Erlotinib
- **RADIATION:** Hypofractionated Radiotherapy

## Key facts

- **NCT ID:** NCT00983307
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-27
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983307, "A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00983307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*